MUSTACCHI G.

Last name: MUSTACCHI G.

2016 (v1)

Publication

Metadata-only

Corrigendum to "Gene expression profiling in breast cancer: A clinical perspective" [The Breast 22 (2013) 109-120 [doi:10.1016/j.breast.2013.01.016.]]

Arpino G. Generali D. Sapino A.

No description

Uploaded on: May 12, 2023
2021 (v1)

Publication

Metadata-only

Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

Schettini F. Giuliano M. Lambertini M.

Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non‐pegylated liposomal doxorubicin (NPLD) has been developed to optimize the toxicity profile induced...

Uploaded on: April 14, 2023
2020 (v1)

Publication

Metadata-only

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

Cazzaniga M. E. Verusio C. Ciccarese M.

Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of...

Uploaded on: April 14, 2023

MUSTACCHI G.

Recent uploads